Renaissance’s non-GMO acrylamide-reducing yeast is a clean-label ingredient that reduces the formation of acrylamide in many common foods, including chips, crackers, bread, cereals and many other everyday foods and snacks

Vancouver, Canada — November 7, 2023 — Renaissance BioScience Corp., a leader in bioengineering for the global food industry, is pleased to announce that it has recently been granted patents for its non-GMO acrylamide-reducing yeast from regulatory authorities in Denmark, France, Great Britain, Italy, Sweden, Mexico, Ukraine, and South Africa. These patents join its portfolio of patents in ten other key markets, further strengthening the company’s intellectual property position.  

Renaissance’s CSO and Office of the CEO, Dr. John Husnik commented on the newly granted patents: “Acrylamide is a global public health concern, particularly for our children, who consume more than adults due to their daily diet of many common foods that unfortunately contain this carcinogen and neurotoxin. We are pleased that our acrylamide-reducing yeast is finding acceptance and being commercialized by food manufacturers in markets all around the world to reduce the presence of this contaminant in their products. Receiving these additional patent grants is important to protect the use of our acrylamide-reducing yeast in many different and important food manufacturing applications.”

The Fight Against Acrylamide 

Acylamide, a probable carcinogen and genotoxin and confirmed neurotoxin, forms naturally when carbohydrate-rich foods like rice, grains and potatoes are cooked at temperatures above 120°C (248°F). Prolonged acrylamide consumption is linked to increased risk of neurological disorders, metabolic syndrome, cardiovascular disease and obesity. 

In addition, recent studies are showing links between acrylamide consumption and human neurological and neurodivergent mental health issues, including anxiety and depression. Acrylamide was first discovered to be widespread in many different foods worldwide in the early 2000s and since then, has prompted a number of regulatory bodies worldwide to increasingly regulate its presence in foods and beverages as a significant public health issue.  

These increasing acrylamide regulations are leading manufacturers to search for a clean-label solution to reduce acrylamide in their products while maintaining the same quality and costs.  

The Solution: Acrylamide-Reducing-Yeast 

Renaissance created a non-GMO, organic suitable yeast, sold globally as Acryleast™ and Acryleast Pro™, and as Acrylow™ in Scandinavia, which is used in standard manufacturing processes to naturally reduce acrylamide levels by up to 90%. The products supplied by Renaissance’s partners, Kerry Group, a global leader in sustainable nutrition, and Orkla Food Ingredients, a leading supplier of branded consumer goods, allow food manufacturers to drastically reduce the acrylamide content of their products with minimal to no disruption on their operations. 

About Renaissance BioScience Corp.

Headquartered in Vancouver, Canada, Renaissance is a leading bioengineering company whose platform technologies are used to develop innovative, market-ready, functional microorganisms to address a broad range of environmental, health and industrial challenges. Renaissance technologies create products for multiple end-use industries, including food & beverage, agriculture, animal and human health and energy. Detailed information about the Renaissance group of companies is available at www.renaissancebioscience.com.

For further information or to arrange interviews, please contact: 

Steve Campbell

Campbell & Company Strategies Inc.

Communications and Public Relations

01 604 888-5267

renaissance@ccom-pr.com

For commercial or technology development inquiries, please contact:

Reesha Parmar

Manager - Business Development and Strategy

rparmar@renaissancebioscience.com

Caution Regarding Forward-Looking Statements

This press release may include forward-looking statements with respect to the Company based on management’s opinions, estimates and assumptions considering its experience and perception of historical trends, current conditions and expected future developments, as well as other factors that management currently believes are appropriate and reasonable in the circumstances. Generally, forward-looking statements can be identified using terminology such as “anticipate”, “will”, “expect”, “may”, “continue”, “could”, “estimate”, “forecast”, “plan”, “potential” and similar expressions. The forward-looking statements contained in this press release are made as of the date hereof.  

Forward-looking statements contained in this press release may include, but are not limited to: statements with respect to the successful execution of the Company's business and investment strategy (including its business model), the Company’s intellectual property, entrance of the Company’s business into new markets, the use and benefits of its products and services, the Company’s favourable position in the market on a go-forward basis, demographic and market size/trends, forecasts of revenue and financial projections/growth potential, competitive analysis, projected milestones, go-forward management, go-forward capitalization, anticipated governmental and regulatory approvals and other expectations, beliefs, plans, objectives, assumptions, intentions or statements about future events or performance, review and approval dates, start-up timelines and schedules and statements related to the continued overall advancement of the Company’s business.  

By their nature, forward-looking statements are subject to a variety of factors that could cause actual results to differ materially from the results suggested by the forward-looking statements. In addition, the forward-looking statements require the Company to make assumptions and are subject to inherent risks and uncertainties. Despite a careful process to prepare and review the forward-looking information, there can be no assurance that the underlying opinions, estimates and assumptions will prove to be correct. There is significant risk that the forward-looking statements will not prove to be accurate, that the Company’s assumptions may not be correct and that actual results may differ materially from such forward-looking statements. Accordingly, readers should not place undue reliance on the forward-looking statements. 

Except as required by law, the Company undertakes no obligation to update publicly or to revise any forward-looking statements that are contained or incorporated in this press release. All forward-looking statements contained in this press release are expressly qualified by this cautionary statement.

Back to all news